THMO: ThermoGenesis Holdings EV/EBITDA Multiple

ThermoGenesis (THMO) technologies are patent-protected, and the deep integration of their systems into laboratory workflows makes it difficult for clients to switch to other equipment. This daily price chart on GURU.Markets with the indicator links these advantages to a sales model where instrument installation guarantees a steady stream of revenue from proprietary consumables. Demand is currently growing as commercial biobanks seek to automate cell isolation.

Cesca Therapeutics - THMO Enterprise Value to EBITDA Ratio (period 07/04/2022 - 11/10/2026)

Summary analytical data breakdowns for thermogenesis.com (THMO)

- stock price and consensus target price:

Stock Quotes ThermoGenesis Holdings Inc.|THMO - Analyst Forecast Prices

- market capitalization information:

Market Capitalization Cesca Therapeutics|THMO - Company Buyout Price

- issuer book value statistics:

Book Value per Share ThermoGenesis|THMO - Company Net Assets|Market Cap to Net Assets Ratio thermogenesis.com|THMO - Aggregate Asset Value

- company liabilities and liquidity data:

- financial results and valuation multiples details:

THMO - Net Income|Projected Future Earnings ThermoGenesis|THMO - P/E Multiple|Future Price to Earnings ThermoGenesis|THMO - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Cesca Therapeutics|THMO - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) ThermoGenesis|THMO - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months thermogenesis.com|THMO - Net earnings per share change in current year|Expected earnings per share growth for next year ThermoGenesis

Initial company analysis:ThermoGenesis Holdings Inc. THMO

The production of high-precision blood processing systems at ThermoGenesis requires significant capital expenditures and adherence to strict ESG standards for waste disposal. This metric aggregates market capitalization and net debt, comparing them against operating profit before depreciation and amortization. The assessment of debt management efficiency and the real value of the business becomes evident when analyzing the trend of the Enterprise Value to EBITDA multiple.

Competitor analysis for ThermoGenesis

Abbott Laboratories Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TMO (Thermo Scientific)|GE HealthCare - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio mt.com MTD|WAT: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Bio-Techne Corp|Enterprise Value to EBITDA Ratio BRKR|AZTA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Varex Imaging (VREX)|Enterprise Value to EBITDA Ratio semlerscientific.com SMLR|EV/EBITDA Multiple BFLY (Butterfly Network)|Mesa Laboratories Inc (MLAB) - Company Value to EBITDA|Quantum-Si Corp - EV/EBITDA Multiple|NNOX (Nano-X Imaging Ltd) - Enterprise Value to Operating Income Before Depreciation|QTRX: EV/EBITDA Multiple|MASS - Total Company Value to Operating Income Before Depreciation Ratio|CV (CapsoVision, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio MaxCyte Inc. (MXCT)|EV/EBITDA Multiple RPID|EV/EBITDA Multiple Seer Bio (SEER)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Hyperfine, Inc. HYPR|fonar.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|DXR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation MDAI (spectral-ai.com)|VIVS: EV/EBITDA Multiple|Company Value to EBITDA Aclarion Corporation (ACON)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Akoya Biosciences Inc|TLIS - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio TTOO (T2 Biosystems)